This 10th edition conference on Strategic Alliance Management for Pharma will focus on demonstrating the value and role of alliance management, strengthening the skills of alliance function, aligning the right resources and projects,
The primary goal of this conference is to promote research and developmental activities in pharmaceutical sciences while enabling scientific information interchange between researchers, industries, students and practitioners working in this
Are you aware of new European Nitrosamine Regulations - EMA/511347/2019. There is serious workload expected from all marketing authorisation holders (MAH) in EU! Let’s see what is expected for MAH
PHARMA COLLOQUIUM 2020 is an arena for interdisciplinary exchange among professionals in the fields of pharmaceutical technology and its related aspects. Pharma Colloquium 2020 incorporates about each stage of information,
The Pharmacovigilance World 2020 conference will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and contribute
The 4th Annual Digi-Tech Pharma & AI 2020 conference brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare industry. Meet the
The 4th Annual Global Clinical Trials Connect 2020 will provide a platform to discuss on the futuristic advancements in clinical trials and clinical research. This multidisciplinary program involves broad participation of people from clinical
Traditional Medicine-2020 will follow the very best features of 2019 includes Plenary and Keynote lectures by eminent from around the world in addition to contribute papers both oral and poster presentations
What is a biological medicinal product? A biological medicinal product is a medicinal product that contains an active substance produced or excreted from biological sources (human, animal, or microbiological). Due
In August 2017, the Brazilian Health Surveillance Agency (ANVISA) published Resolution No. 168/2017, which establishes the administrative procedures related to ANVISA´s “prior consent” for the granting of pharmaceutical patent applications,
